Display options
Cite
Nardi A, Ventura L, Cozzi L, et al. Clodronate news of efficacy in osteoporosis. Clin Cases Miner Bone Metab. 2016;13(1):33-5doi: 10.11138/ccmbm/2016.13.1.033.
Nardi, A., Ventura, L., Cozzi, L., & Tonini, G. (2016). Clodronate news of efficacy in osteoporosis. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 13(1), 33-5. https://doi.org/10.11138/ccmbm/2016.13.1.033
Nardi, Alfredo, et al. "Clodronate news of efficacy in osteoporosis." Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases vol. 13,1 (2016): 33-5. doi: https://doi.org/10.11138/ccmbm/2016.13.1.033
Nardi A, Ventura L, Cozzi L, Tonini G. Clodronate news of efficacy in osteoporosis. Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):33-5. doi: 10.11138/ccmbm/2016.13.1.033. Epub 2016 May 11. PMID: 27252741; PMCID: PMC4869950.
Copy Download .nbib Format: NLM
Share it on

Clin Cases Miner Bone Metab. 2016 Jan-Apr;13(1):33-5. doi: 10.11138/ccmbm/2016.13.1.033. Epub 2016 May 11.

Clodronate news of efficacy in osteoporosis.

Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases

Alfredo Nardi, Lorenzo Ventura, Luisella Cozzi, Greta Tonini

Affiliations

  1. Company ULSS 18, Rovigo, Italy.
  2. Hospital Carlo Poma, Mantova, Italy.

PMID: 27252741 PMCID: PMC4869950 DOI: 10.11138/ccmbm/2016.13.1.033

Abstract

Clodronate belongs to Bisphosphonates family and it has been studied especially for osteoporosis treatment, Paget's disease, osteolytic metastases, hypercalcemia malignancy and some childhood skeletal diseases. Besides the osteoporosis treatment, it has been successfully used for treating tumoral osteolysis and for bone localization of multiple myeloma, hypercalcemia malignancy, primary hyperparathyroidism, Paget's disease and algodystrophy. Filipponi study showed a statistically significant reduction of the incidence of vertebral fractures after 4 years of treatment with clodronate, intravenously administered at a dose of 200 mg every three weeks. Frediani study, published in 2003 on BONE, proved the clodronate efficacy in the prevention of fractures caused by glucocorticoid-induced osteoporosis (GIO). Clodronate doses of 800 mg/day per os and 100 mg i.m./week are substantially equivalent, because the oral absorption is about 1,9%. A higher efficacy on BMD was documented in various works, especially in cohorts of patients with a greater fracture risk, using higher doses (1600 mg per os). This has led to the hypothesis of using clodronate 200 mg i.m. formulation. Clodronate is an osteoporosis drug that can be assumed in different doses (100 mg i.m./week, clodronate 200 mg i.m. every 2 weeks) considering the risk band, identified by algorithms (FRAX o DeFRA), by BMD and by the presence of at least one risk factor. That means that it is possible to envisage a differentiated use of clodronate adapting the doses to the fracture risk and to the severity of pain symptoms, thus promoting a greater adherence to the therapy. To conclude clodronate is helpful in reducing fracture risk, is safe, well tolerated, and has a good rate cost/effectiveness in patients with fracture risk over 7% established with FRAX.

Keywords: BMD; GIO; adherence; bisphosphonates; clodronate; cost-effectiveness; fracture risk reduction; prevention fractures

References

  1. Drug Des Devel Ther. 2011;5:445-54 - PubMed
  2. J Bone Miner Res. 2004 May;19(5):728-36 - PubMed
  3. J Rheumatol. 2000 Aug;27(8):1980-3 - PubMed
  4. Osteoporos Int. 2010 Jun;21 Suppl 2:S407-13 - PubMed
  5. J Bone Miner Res. 2007 Jan;22(1):135-41 - PubMed
  6. Bone. 1996 Feb;18(2):179-84 - PubMed
  7. Inflamm Res. 2000 Aug;49(8):424-33 - PubMed
  8. Osteoporos Int. 2009 May;20(5):811-7 - PubMed
  9. Rheumatol Int. 2009 Dec;30(2):213-21 - PubMed
  10. Osteoporos Int. 2007 Aug;18(8):1033-46 - PubMed
  11. Br J Pharmacol. 2000 Aug;130(7):1646-54 - PubMed
  12. Clin Drug Investig. 2009;29(6):359-79 - PubMed
  13. Clin Drug Investig. 2011;31(1):43-50 - PubMed
  14. Expert Opin Pharmacother. 2002 Nov;3(11):1643-56 - PubMed
  15. Drugs Aging. 2004;21(14):949-62 - PubMed

Publication Types